Therefore, we tested ERAD pathway dependence in resistant and sensitive breast cancer cells by applying a clinical drug candidate, CB-5083, which targets the p97 ATPase domain (Zhou et al., 2015). This evidence concerns the gene DNAH8 and breast carcinoma.